<DOC>
	<DOCNO>NCT00535340</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy SR58611A 350 mg twice day compare placebo elderly patient Generalized Anxiety Disorder ( GAD ) , assess 14-item Hamilton Anxiety rating Scale ( HAM-A ) . Secondary objective evaluate tolerability safety SR58611A elderly patient GAD , evaluate efficacy SR58611A compare placebo disablility quality life elderly patient GAD evaluate tolerability safety 24 week additional treatment SR58611A elderly patient GAD .</brief_summary>
	<brief_title>An Eight-Week Study Evaluate Efficacy Safety SR58611A Elderly Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<criteria>Patients diagnose Generalized Anxiety Disorder ( GAD ) define Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) criterion support Mini International Neuropsychiatric Interview ( MINI ) plus Generalized Anxiety Disorder module Minimum total score less 22 14item HAMA scale Total score 18 high MontgomeryAsberg Depression Rating Scale ( MADRS ) MiniMental State Examination ( MMSE ) score 22 less The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>Anti-Anxiety Agents</keyword>
</DOC>